-
With three first-in-human trials, therapeutic stem cell science takes a bold step
University of California, San Diego Health Sciences reports on the first of four patients, who was treated in late September 2014, in the commencement of Neuralstem’s Phase I NSI-566/chronic spinal cord injury (cSCI) trial. The Science Daily story reviews this first FDA-approved trial for cSCI as one of three ground-breaking stem cell efforts underway at UCSD, supported by the Sanford Stem Cell Clinical Center.